News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ImmuCell (ICCC) Announces Product Sales Growth and Profit



5/14/2012 8:27:23 AM

PORTLAND, ME--(Marketwire - May 14, 2012) - ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three-month period ended March 31, 2012.

During the three-month period ended March 31, 2012, product sales increased by 10%, or $161,000, to $1,717,000 in comparison to the same period in 2011. During the twelve-month period ended March 31, 2012, product sales increased by 14%, or $642,000, to $5,273,000 in comparison to the same period in 2011.

"A 13% increase in sales of our lead product, First Defense®, during the first three months of 2012 over the same period in 2011, demonstrates a solid return on our increased investment in sales and marketing," commented Michael F. Brigham, President and CEO. "Based primarily on increased gross margin from sales of First Defense® and the anticipated reduction in product development expenditures, we returned to profitable operations for the first time since the first quarter of 2008."

Income before income taxes was $271,000 during the three-month period ended March 31, 2012, in contrast to a loss before income taxes of ($31,000) during the same period in 2011. Net income was $155,000, or $0.05 per share, during the three-month period ended March 31, 2012, in contrast to a net loss of ($23,000), or ($0.01) per share, during the same period in 2011.

Cash, cash equivalents and short-term investments increased by 2%, or $95,000, to $5,054,000 at March 31, 2012 as compared to $4,960,000 at December 31, 2011. Stockholders' equity increased by 3%, or $227,000, to $9,247,000 at March 31, 2012 as compared to $9,020,000 at December 31, 2011. The Company had 3,019,000 shares of common stock outstanding as of March 31, 2012.

(Unaudited) Three-Month Periods Ended March 31, -------------------- (In thousands, except per share amounts) 2012 2011 --------- --------- Product sales $ 1,717 $ 1,556 Costs of goods sold 705 687 --------- --------- Gross margin 1,012 869 Product development expenses 248 472 Sales, marketing and administrative expenses 483 414 --------- --------- Other operating expenses 731 886 --------- --------- NET OPERATING INCOME (LOSS) 281 (17) Other (expenses) revenues, net (10) (14) --------- --------- INCOME (LOSS) BEFORE INCOME TAXES 271 (31) Income tax expense (benefit) 116 (8) --------- --------- NET INCOME (LOSS) $ 155 $ (23) ========= ========= Weighted average common shares outstanding: Basic 3,016 2,974 Diluted 3,103 2,974 NET INCOME (LOSS) PER SHARE: Basic $ 0.05 $ (0.01) Diluted $ 0.05 $ (0.01) (Unaudited) At March 31, At December 31, (In thousands) 2012 2011 --------------- --------------- Cash, cash equivalents and short-term investments $ 5,054 $ 4,960 Total assets 11,171 10,991 Net working capital 6,780 6,516 Stockholders' equity $ 9,247 $ 9,020

About ImmuCell:
ImmuCell Corporation's (NASDAQ: ICCC) purpose is to create scientifically-proven and practical products that result in a measurable economic impact on animal health and productivity in the dairy and beef industries. Press releases and other information about the Company are available at our web-site, (http://www.immucell.com).


Contact:
Michael F. Brigham
President and Chief Executive Officer
(207) 878-2770 Ext. 3106


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES